NO20092398L - Krystallinske former av solvatisert ilaprazol - Google Patents

Krystallinske former av solvatisert ilaprazol

Info

Publication number
NO20092398L
NO20092398L NO20092398A NO20092398A NO20092398L NO 20092398 L NO20092398 L NO 20092398L NO 20092398 A NO20092398 A NO 20092398A NO 20092398 A NO20092398 A NO 20092398A NO 20092398 L NO20092398 L NO 20092398L
Authority
NO
Norway
Prior art keywords
ilaprazole
crystalline forms
methyl
secretion
relates
Prior art date
Application number
NO20092398A
Other languages
English (en)
Norwegian (no)
Inventor
John M Brackett
David T Jonaitis
Wei Lai
Stephan D Parent
Original Assignee
Il Yang Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Il Yang Pharm Co Ltd filed Critical Il Yang Pharm Co Ltd
Publication of NO20092398L publication Critical patent/NO20092398L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO20092398A 2006-12-29 2009-06-24 Krystallinske former av solvatisert ilaprazol NO20092398L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87760806P 2006-12-29 2006-12-29
US88749907P 2007-01-31 2007-01-31
PCT/US2007/089137 WO2008083341A1 (fr) 2006-12-29 2007-12-28 Formes cristallines d'ilaprazole solvaté

Publications (1)

Publication Number Publication Date
NO20092398L true NO20092398L (no) 2009-09-28

Family

ID=39313094

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20092398A NO20092398L (no) 2006-12-29 2009-06-24 Krystallinske former av solvatisert ilaprazol
NO20092464A NO342530B1 (no) 2006-12-29 2009-06-29 Faste former av rasemisk ilaprazol

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20092464A NO342530B1 (no) 2006-12-29 2009-06-29 Faste former av rasemisk ilaprazol

Country Status (19)

Country Link
US (4) US7989632B2 (fr)
EP (2) EP2102192B1 (fr)
JP (2) JP5315253B2 (fr)
KR (3) KR20110091594A (fr)
CN (2) CN101687848B (fr)
AU (2) AU2007341992B2 (fr)
CA (2) CA2674358C (fr)
DK (1) DK2102192T3 (fr)
ES (1) ES2398846T3 (fr)
HK (2) HK1140483A1 (fr)
IL (2) IL199234A (fr)
MX (2) MX2009006529A (fr)
MY (2) MY146462A (fr)
NO (2) NO20092398L (fr)
NZ (2) NZ577129A (fr)
PL (1) PL2102192T3 (fr)
PT (1) PT2102192E (fr)
RU (2) RU2466129C2 (fr)
WO (2) WO2008083333A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101144600B1 (ko) * 2009-12-08 2012-05-16 일양약품주식회사 일라프라졸의 결정형 ａ, ｂ의 제조방법 및 이들 결정형의 변환방법
CN103204843B (zh) * 2012-01-13 2014-12-31 丽珠医药集团股份有限公司 结晶型艾普拉唑钠乙醇化物及其制备方法
CN103204842B (zh) * 2012-01-13 2014-10-15 丽珠医药集团股份有限公司 结晶型艾普拉唑钠水合物及其制备方法
WO2013114232A1 (fr) * 2012-02-02 2013-08-08 Lupin Limited Procédé de préparation de forme cristalline l d'ilaprazole
CN102746277B (zh) * 2012-06-21 2014-05-14 丽珠医药集团股份有限公司 一种结晶形式的艾普拉唑钠及其制备方法
CN102746275B (zh) * 2012-06-21 2014-07-16 丽珠医药集团股份有限公司 结晶型艾普拉唑钠及其制备方法
CN103172618B (zh) * 2013-02-27 2014-09-03 丽珠医药集团股份有限公司 艾普拉唑晶型及其制备方法
CN104370886B (zh) * 2014-11-18 2016-05-18 宁夏康亚药业有限公司 艾普拉唑晶型及其制备方法和应用
CN105055342A (zh) * 2015-08-13 2015-11-18 青岛蓝盛洋医药生物科技有限责任公司 一种治疗消化性溃疡的药物艾普拉唑钠组合物冻干粉针剂
CN105055343A (zh) * 2015-08-31 2015-11-18 青岛蓝盛洋医药生物科技有限责任公司 一种治疗胃病的药物艾普拉唑钠组合物冻干粉针剂
CN106749191A (zh) * 2016-12-10 2017-05-31 珠海保税区丽珠合成制药有限公司 艾普拉唑晶型ⅱ及其制备方法
KR101961028B1 (ko) * 2017-10-12 2019-03-21 중앙대학교 산학협력단 일라프라졸을 유효성분으로 함유하는 급성 위염의 예방 또는 치료용 약학 조성물
KR102332996B1 (ko) * 2020-04-13 2021-12-01 중앙대학교 산학협력단 일라프라졸을 유효성분으로 함유하는 장폐색증 예방 또는 치료용 약학조성물
KR20220065235A (ko) 2020-11-13 2022-05-20 주식회사 파마코스텍 일라프라졸 혼형 결정의 신규한 제조방법
KR102250509B1 (ko) * 2020-12-09 2021-05-11 유니셀랩 주식회사 새로운 일라프라졸/자일리톨 공결정
KR20210019469A (ko) 2021-02-02 2021-02-22 주식회사 파마코스텍 일라프라졸 나트륨 결정형 및 신규한 제조방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0179401B1 (ko) * 1994-02-28 1999-03-20 송택선 신규한 5-피롤릴-2-피리딜메틸설피닐벤즈이미다졸 유도체
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
RU2232159C2 (ru) * 1999-07-29 2004-07-10 Регентский Совет Университета Калифорнии Производные бензимидазола и фармацевтические композиции, содержащие пролекарство ингибитора протонного насоса
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
KR20040093187A (ko) 2002-03-27 2004-11-04 테바 파마슈티컬 인더스트리즈 리미티드 란소프라졸 다형 및 그것의 제조 방법
JP4837722B2 (ja) 2005-03-25 2011-12-14 リブゾン ファーマシューティカル グループ インク． 置換スルホキシド化合物、その調製方法、およびその使用方法
EP1879577A1 (fr) * 2005-05-04 2008-01-23 AstraZeneca AB Inhibiteurs de la pompe a protons dans le traitement des troubles du sommeil provoques par un reflux gastro-oesophagien silencieux

Also Published As

Publication number Publication date
AU2007341984B2 (en) 2012-07-05
HK1140484A1 (en) 2010-10-15
CN101687849A (zh) 2010-03-31
IL199242A (en) 2013-10-31
US8592600B2 (en) 2013-11-26
CA2674347A1 (fr) 2008-07-10
JP5315254B2 (ja) 2013-10-16
US20110082174A1 (en) 2011-04-07
NZ577509A (en) 2012-01-12
RU2466129C2 (ru) 2012-11-10
EP2102192B1 (fr) 2012-11-14
PT2102192E (pt) 2013-01-23
RU2009122241A (ru) 2011-02-10
KR20110091594A (ko) 2011-08-11
US20110046184A1 (en) 2011-02-24
US7999110B2 (en) 2011-08-16
EP2102191B1 (fr) 2012-11-21
KR101052387B1 (ko) 2011-07-28
JP2010514807A (ja) 2010-05-06
AU2007341992B2 (en) 2012-07-05
JP2010514806A (ja) 2010-05-06
AU2007341984A1 (en) 2008-07-10
CN101687849B (zh) 2013-05-29
US8592599B2 (en) 2013-11-26
DK2102192T3 (da) 2013-03-04
KR20090086615A (ko) 2009-08-13
CN101687848B (zh) 2013-05-15
WO2008083333A1 (fr) 2008-07-10
US7989632B2 (en) 2011-08-02
CA2674358A1 (fr) 2008-07-10
MX2009006529A (es) 2009-08-18
CN101687848A (zh) 2010-03-31
JP5315253B2 (ja) 2013-10-16
EP2102192A1 (fr) 2009-09-23
US20080200516A1 (en) 2008-08-21
EP2102191A1 (fr) 2009-09-23
PL2102192T3 (pl) 2013-04-30
HK1140483A1 (en) 2010-10-15
CA2674347C (fr) 2013-08-06
CA2674358C (fr) 2013-10-08
WO2008083341A1 (fr) 2008-07-10
RU2009122242A (ru) 2011-02-10
MY146462A (en) 2012-08-15
RU2464270C2 (ru) 2012-10-20
ES2398846T3 (es) 2013-03-22
NO342530B1 (no) 2018-06-11
NO20092464L (no) 2009-09-28
MX2009006530A (es) 2009-08-18
KR20090086121A (ko) 2009-08-10
IL199234A (en) 2013-07-31
AU2007341992A1 (en) 2008-07-10
NZ577129A (en) 2012-02-24
US20080200517A1 (en) 2008-08-21
MY145936A (en) 2012-05-31

Similar Documents

Publication Publication Date Title
NO20092398L (no) Krystallinske former av solvatisert ilaprazol
UA96308C2 (ru) Антагонисты рецептора глюкагона, композиция, которая содержит такие соединения, и их применение
NO20083923L (no) Pyrazolkinoloner er potente parp-inhibitorer
WO2007136577A3 (fr) Composés antagonistes du récepteur du glucagon, compositions contenant ces composés, et procédés d'utilisation
MX2012005358A (es) Procedimiento para la preparacion de etexilato de dabigatran.
NO20075082L (no) Pyridin-3-karboksamidderivater som CB1-inversagonister
WO2008048981A3 (fr) Antagonistes d'indole du récepteur p2y1 utiles dans le traitement d'états thrombotiques
IL196543A (en) Pyridazinone derivatives, pharmaceutical preparations containing them for use in the treatment of disorders
NO20084489L (no) Azolopyrimidiner som inhibitorer av cannabinoid 1 aktivitet
WO2008076243A3 (fr) Composés acyl-bipipéridinyle, compositions contenant de tels composés et procédés de traitement
HK1135703A1 (en) Piperidine gpcr agonists
WO2007120689A3 (fr) Procédés d'utilisation du récepteur gpr119 pour identifier des composés utiles pour augmenter la masse osseuse chez un individu
EA200900091A1 (ru) Новые показания к применению прямых ингибиторов тромбина в лечении сердечно-сосудистых заболеваний
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
NO20052474L (no) Amort form av esomeprazolsalter
WO2007120575A3 (fr) Agonistes du récepteur de la niacine, compositions contenant de tels composés et méthodes de traitement
WO2006057922A3 (fr) Agonistes des recepteurs de la niacine, compositions contenant ces composes et methodes de traitement
NO20083836L (no) N-hydroksyakrylamidforbindelser
WO2008051403A3 (fr) Agonistes de récepteur de niacine, compositions contenant ces composes et procédés de traitement
GEP20125649B (en) Benzimidazole compound crystal
MX2009004140A (es) Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintasa quinasa 3.
HK1104035A1 (en) Crystalline esomeprazole strontium hydrate, method for preparing the same and pharmaceutical composition containing the same
NO20091331L (no) Nitrogenholdige substituerte heterocykler som blodplate ADP reseptorinhibitorer
WO2007138468A3 (fr) Procédés de préparation de lansoprazole
WO2008097468A3 (fr) Antagonistes sélectifs des récepteurs de type a de l'endothéline

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application